W

hen the Food and Drug Administration last week issued guidelines for investigative stem cell therapies, much of the attention fell to the agency’s vow to crack down further on unregulated clinics offering potentially unsafe treatments.

But the guidances also have plenty of ramifications for companies trying to bring to market innovative and legitimate stem cell treatments by moving them through clinical trials and getting them approved by the FDA.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.